Major trial aims to spare breast cancer patients from chemotherapy
NCT ID NCT07391774
Summary
This large, Phase 3 trial is testing if a gentler treatment plan works as well as a stronger one for a specific type of breast cancer. It will enroll nearly 2,000 postmenopausal women and men with high-stage, hormone-sensitive, HER2-negative breast cancer that has a low genetic risk of returning. The study compares standard hormone therapy plus a targeted drug (ribociclib) against the current standard of chemotherapy followed by that same hormone and targeted drug combination.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANATOMIC STAGE II BREAST CANCER AJCC V8 are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.